These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 6547367

  • 1. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC, Glick JH, Cross J, Horton J, Taylor SG.
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [Abstract] [Full Text] [Related]

  • 2. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [Abstract] [Full Text] [Related]

  • 3. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A, Albanell J, Solé-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, Baselga J.
    Cancer; 1998 Mar 01; 82(5):878-85. PubMed ID: 9486577
    [Abstract] [Full Text] [Related]

  • 4. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone.
    Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR.
    Cancer Treat Rep; 1984 Mar 01; 68(7-8):1039-41. PubMed ID: 6547638
    [Abstract] [Full Text] [Related]

  • 5. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O, Del Mastro L, Mariani GL, Ardizzoni A, Venturini M, Rosso R.
    Minerva Med; 1993 Sep 01; 84(9):467-72. PubMed ID: 7504219
    [Abstract] [Full Text] [Related]

  • 6. Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study.
    Kaye SB, Sangster G, Hutcheon A, Habeshaw T, Crossling F, Ferguson C, McArdle C, Smith D, George WD, Calman KC.
    Cancer Treat Rep; 1984 Mar 01; 68(3):547-8. PubMed ID: 6704984
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA.
    Cancer; 1997 Feb 15; 79(4):740-8. PubMed ID: 9024712
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul 15; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y, Tominaga T, Adachi I, Koyama H, Fukami A.
    Gan To Kagaku Ryoho; 1994 Sep 15; 21(12):1949-56. PubMed ID: 8085846
    [Abstract] [Full Text] [Related]

  • 16. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
    Mortimer J, Livingston RB, Hardesty IJ, Groppe CW, Purvis JD, Gupta M, Flournoy N.
    Cancer Treat Rep; 1984 Sep 15; 68(7-8):1017-8. PubMed ID: 6744334
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 18. [Systemic chemotherapy of mammary carcinoma: plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer].
    Murayama Y, Nagashima M.
    Gan To Kagaku Ryoho; 1984 Mar 01; 11(3):415-9. PubMed ID: 6546655
    [Abstract] [Full Text] [Related]

  • 19. [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
    Zhou JC.
    Zhonghua Zhong Liu Za Zhi; 1993 May 01; 15(3):215-7. PubMed ID: 8261870
    [Abstract] [Full Text] [Related]

  • 20. [The clinical efficacy of CAC regimen in the treatment of advanced breast cancer].
    Zhang P, Zhou J, Feng F.
    Zhonghua Zhong Liu Za Zhi; 1995 Sep 01; 17(5):365-7. PubMed ID: 8697977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.